Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
artemether + lumefantrine + sulfadoxine + pyrimethamine
- Development stage
- Unknown
- Lead developer
- Institute of Tropical Medicine Antwerp
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This entry refers to a combination of four antimalarial agents: artemether, lumefantrine, sulfadoxine, and pyrimethamine. In the context of clinical research by the Institute of Tropical Medicine, Belgium, these agents were evaluated as two distinct fixed-dose combinations—artemether-lumefantrine (marketed as Coartem) and sulfadoxine-pyrimethamine (marketed as Fansidar or SP)—to compare their safety and efficacy in treating uncomplicated *Plasmodium falciparum* malaria in Zambia, particularly among HIV-infected and non-infected adults. Artemether and lumefantrine act by generating reactive free radicals and inhibiting hemozoin formation, respectively, providing rapid parasite clearance and long-acting suppression. Sulfadoxine and pyrimethamine act synergistically to inhibit sequential steps in the parasite's folic acid synthesis pathway, targeting dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR).
- Brand names
- Fansidar
- Other names
- artemether-lumefantrinesulfadoxine-pyrimethamineALSP
02
Targets
HemeDHPS (Dihydropteroate synthase)PfATP4 (Plasmodium falciparum ATPase 4)DHFR (Dihydrofolate reductase)
Beyond the preview
Go deeper on artemether + lumefantrine + sulfadoxine + pyrimethamine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on artemether + lumefantrine + sulfadoxine + pyrimethamine.